Step Therapy Explained: Rules, Exceptions, Appeals & Insurance Coverage

Step therapy (also called “fail first”) is an insurance coverage rule that requires patients to try one or more preferred, lower-cost medications before the health plan covers the drug originally prescribed by their doctor. 

Payers, pharmacy benefit managers, and Medicare plans use step therapy as a utilization management tool to control prescription drug spending by directing patients toward generic, biosimilar, or formulary-preferred alternatives first. 

When the preferred medication fails, causes adverse reactions, or is contraindicated, the prescriber can request a step-therapy exception to move the patient to the originally prescribed drug.

Here is what the rest of this guide covers

• How step therapy differs from prior authorization
• Which drug categories commonly face step therapy requirements
• How step therapy works at the pharmacy, prescriber, and payer level
• How providers can request exceptions and build strong documentation
• When step therapy is clinically reasonable and when it causes harm
• How rules vary by plan type, state, and Medicare coverage
• What happens when an exception is denied

How does step therapy work?

Step therapy follows a predictable sequence, though patients and providers often encounter it as a surprise at the pharmacy counter.

The prescriber writes a prescription based on the patient’s diagnosis, treatment history, disease severity, and clinical guidelines. 

The pharmacy submits the claim to the health plan or PBM, and if the drug is subject to step therapy, the claim is rejected with a step edit — an electronic flag indicating that the plan requires a different medication first.

At that point, the prescriber has two options:

1. Switch to the plan’s preferred drug if it is clinically safe and appropriate
2. Submit an exception request with documentation explaining why the preferred drug is not suitable for the patient

If the exception is approved, the originally prescribed medication is covered. If denied, the prescriber and patient may file an appeal, request an expedited review (when delay could cause harm), or pursue external review depending on the plan type and state law.

A 2024 study on mandated step therapy for dupilumab in atopic dermatitis found that the requirement caused an average treatment delay of 4.6 months and 1.4 additional clinic appointments before patients could begin effective therapy. 

Patients subject to step therapy needed an additional 112 days to reach symptom improvement compared with those who started treatment directly.

How does step therapy differ from prior authorization?

Step therapy and prior authorization are both utilization management tools, but they address different coverage questions. 

Patients and providers often confuse them because a step therapy exception is frequently handled through the prior authorization process.

Feature	Step therapy	Prior authorization
Main question	Did the patient try the preferred drug first?	Does the plan approve this drug before coverage begins?
Common trigger	Prescribed drug is non-preferred, newer, or more expensive	Drug is high-cost, restricted, or specialty-tier
What the prescriber submits	Prior drug history, trial outcomes, and medical rationale	Clinical criteria, diagnosis, and medical necessity evidence
Can both apply to the same drug?	Yes	Yes

The real source of confusion is that both restrictions can stack. 

A patient may face step therapy and prior authorization for the same medication, with each requiring separate documentation from the prescriber’s office.

What drugs commonly require step therapy?

Step therapy is most common for medications where lower-cost formulary alternatives exist. 

Coverage varies by health plan, PBM, and formulary year, so no drug always requires step therapy — but certain categories are affected far more frequently than others.

Drug category	Why step therapy may apply	Typical first-step requirement
Diabetes medications	Multiple lower-cost options available	Metformin or preferred sulfonylurea
GLP-1 medications (Ozempic, Zepbound, Mounjaro)	High cost and limited coverage	Preferred diabetes or weight-loss alternatives
Biologics for autoimmune disease	High cost and specialty pharmacy handling	Preferred biologic or biosimilar
Migraine preventives	Older drug classes available	Beta blockers, triptans, or preferred alternatives
Cholesterol-lowering drugs	Generic statins widely available	Statin trial before PCSK9 inhibitors
Asthma and COPD inhalers	Multiple inhaler classes exist	Preferred inhaler before specialty option
Mental health medications	Several drug classes overlap	Preferred SSRI or generic before branded alternatives

A 2024 Avalere analysis found that 54% of Medicare Advantage enrollees were in plans requiring step therapy for commonly used rheumatoid arthritis biologics. 

For certain products, 78% of enrollees faced step edits, and 27% of those enrollees faced two or more required steps before reaching the prescribed biologic.

How can providers request a step therapy exception?

A step-therapy exception is a formal request to skip the required step and move directly to the prescribed medication. 

Exception requests succeed most often when the documentation clearly addresses why the required step is clinically inappropriate for the specific patient.

Common grounds for an exception include

• The patient already tried and failed the required drug
• A treatment delay could cause serious or irreversible harm
• The required drug caused an adverse reaction or intolerance
• The patient is stable on the prescribed medication from a prior plan
• The required drug is contraindicated by another condition or medication
• The required drug is expected to be less effective based on clinical evidence
• The required drug conflicts with evidence-based clinical guidelines for the patient’s condition

Medicare.gov states that a prescriber’s supporting statement may explain that the preferred drug is medically necessary to bypass, that the lower-cost option may cause adverse health effects, or that the first-step drug would be less effective for the patient.

For providers, the most common exception mistake is submitting a request that says what drug is needed without explaining why the preferred drug is not appropriate. 

The exception lives or dies on the clinical rationale connecting the patient’s specific situation to the coverage bypass.

What documentation supports a strong exception request?

Strong clinical documentation is the most controllable factor in whether a step therapy exception gets approved. 

Payer reviewers evaluate the exception against coverage criteria, and they can only approve what the submitted records support.

A strong exception submission should include:

• Diagnosis and disease severity
• Relevant lab values or imaging results
• Comorbidities that affect drug selection
• Specialist notes supporting the clinical rationale
• Adverse reactions or intolerances with clinical detail
• Why delaying treatment could worsen the patient’s condition
• Prior drug trials with dates, duration, and documented outcomes
• The required step drug and why it is not appropriate for the patient
• The specific medication requested and why it is medically necessary

The AMA’s 2024 prior authorization survey found that 69% of physicians reported ineffective initial treatments caused at least in part by step therapy requirements. 

Weak documentation	Stronger documentation
“Patient needs Humira.”	“Patient with moderate-to-severe RA tried methotrexate for 12 weeks with persistent disease activity (DAS28 score 5.1). Requires biologic escalation per ACR guidelines.”
“Failed preferred drug.”	“Completed 8-week trial of preferred SSRI with worsening depressive symptoms and documented GI intolerance requiring discontinuation on 04/15/2025.”
“Step therapy not appropriate.”	“Required first-step inhaler contains ingredient patient has documented anaphylactic allergy to (see allergy panel results from 03/2024).”

Documentation that clearly connects the patient’s clinical picture to the rationale for the exception can prevent that outcome before it occurs.

What happens when a step therapy exception is denied?

A denied exception does not end the process. Multiple escalation paths exist depending on the plan type and state regulations.

After denial, providers and patients may pursue several paths

1. Request an internal appeal with additional documentation
2. Ask for an expedited or urgent review when delay could cause clinical harm
3. Pursue external review through an independent review organization (available for most fully insured plans)
4. Invoke state step therapy protections where applicable

As of May 2025, the Aimed Alliance reported that 35 states had enacted some form of step therapy reform. 

Among those states, 33 require exceptions when the required drug has already failed, 32 require exceptions when the drug is contraindicated, and 31 require exceptions when the drug is expected to be ineffective. 

However, only 15 states extended those protections to their Medicaid programs.

How do step therapy rules vary by plan type?

Step therapy rules are not uniform across coverage types, which means the same drug can face different requirements depending on who is paying for it.

Fully insured commercial plans may be subject to state step therapy reform laws. 

Self-insured employer plans governed by ERISA are often exempt from state insurance regulations, leaving employees in those plans without the exception protections their state may have enacted.

For Medicare Part D, CMS treats step therapy waiver requests as formulary exceptions. 

Medicare Advantage plans applying step therapy to Part B drugs must limit the requirement to new prescriptions and maintain at least a 365-day lookback period to verify prior drug use. CMS has stated that Part B step therapy should not disrupt ongoing therapy for patients already receiving a covered drug.

Medicaid step therapy rules vary by state and managed care organization. Providers working across multiple plan types should:

1. Verify the specific step protocol
2. Exception criteria
3. Appeal timelines for each payer

Because what works for one plan may not apply to the next.

When is step therapy clinically reasonable and when does it cause harm?

Step therapy is not inherently harmful. 

When a plan requires a well-studied, guideline-supported first-line medication for a condition where multiple effective options exist, the step can reduce costs without compromising care. 

Generic metformin before a branded GLP-1 for newly diagnosed type 2 diabetes, for example, reflects standard clinical practice.

The harm emerges when protocols ignore patient history, disease severity, prior treatment failure, or the clinical context that makes the required step inappropriate for a specific patient. 

A Health Affairs study found that the share of Medicare Part D drug compounds facing utilization restrictions (including step therapy) rose from 31.9% in 2011 to 44.4% in 2020. 

The expansion makes it more likely that patients with complex conditions will encounter step requirements that don’t fit their clinical situation.

The practical question for providers isn’t whether step therapy exists. It’s whether the documentation is strong enough to get the right patient through the right exception at the right time.

When fail-first denials slow down your practice

Step therapy exceptions and appeals consume real staff time and delay patient treatment — especially when documentation gaps cause preventable denials.

MedHeave helps healthcare providers manage the administrative side of coverage restrictions so clinical teams can stay focused on patient care.

• Prior authorization and exception management across payer formularies
• Denial tracking and appeals support for step therapy-related rejections
• Documentation workflow improvement for medical necessity submissions
• Revenue recovery for improperly denied pharmacy and medical claims

Contact MedHeave to reduce coverage-related denials and protect both revenue and patient access.

Frequently asked questions

Here are some commonly asked questions about step therapy: